Trastuzumab botidotin

博度曲妥珠单抗

Report date: 2026/01/07 16:53:39

Base Information

Drug NameTrastuzumab botidotin
Drug Alias Name注射用A166舒泰莱A-166
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Duostatin-5 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linker
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsTubulin inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Tubulin
Therapy Area/IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[34] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2025/10/14
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSichuan Kelun Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesFudan UniversityKlus Pharma IncSichuan Kelun-Biotech Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[32] 
Inactive IndicationsCarcinoma, Transitional CellNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A